Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics

Abstract Objectives Second generation antipsychotics (SGAs) induce weight gain and dyslipidemia, albeit with important intervariability. Insulin-like growth factor binding protein (IGFBP)-2 is proposed as a circulating biomarker negatively associated with waist circumference and hypertriglyceridemia. Thus, we tested whether metabolic alterations developed upon the use of SGAs are associated with plasma IGFBP-2 levels. Methods A cross-sectional study was performed in 87 men newly diagnosed with schizophrenia and administered for approximately 20 months with olanzapine or risperidone as their first antipsychotic treatment. Plasma IGFBP-2 concentration, anthropometric data, as well as glucose and lipid profiles were determined at the end of the treatments. Results IGFBP-2 levels were similar between patients using olanzapine or risperidone and were negatively correlated with waist circumference, insulin sensitivity, and plasma triglycerides (TG). A higher proportion of men with a hypertriglyceridemic (hyperTG) waist phenotype was found in patients with IGFBP-2 levels lower than 220 ng/mL (43% for olanzapine and 13% for risperidone) compared to those with IGFBP-2 above this threshold (10% and 0%, respectively). Conclusions IGFBP-2 may have a role in altering metabolic risk in schizophrenic patients using SGAs. Longitudinal studies are required to evaluate whether IGFBP-2 can predict the development of a hyperTG waist phenotype in this population.

• Publication year

  2020

• Venue

  World Journal of Biological Psychiatry

• Publication date

  2020-06-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/15622975.2020.1770858PMID 32552257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis

  2020cited by this paper
• Antipsychotics and glucose metabolism: how brain and body collide.

  2019cited by this paper
• Proteins Altered by Surgical Weight Loss Highlight Biomarkers of Insulin Resistance in the Community

  2019cited by this paper
• Changes in IGFBP-2 levels following a one-year lifestyle modification program are independently related to improvements in plasma apo B and LDL apo B levels.

  2019cited by this paper
• Serum IGFBP‐2 levels are associated with reduced insulin sensitivity in obese children

  2018cited by this paper
• The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment

  2018cited by this paper
• Protein Biomarkers of Cardiovascular Disease and Mortality in the Community

  2018cited by this paper
• The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes

  2018cited by this paper
• Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer’s Disease Pathology and Shows Differential Expression in Transgenic Mice

  2018cited by this paper
• Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues

  2018cited by this paper
• Phenotype analysis of male transgenic mice overexpressing mutant IGFBP-2 lacking the Cardin-Weintraub sequence motif: Reduced expression of synaptic markers and myelin basic protein in the brain and a lower degree of anxiety-like behaviour.

  2017cited by this paper
• Cardiorespiratory Fitness in Severe Mental Illness: A Systematic Review and Meta-analysis

  2017cited by this paper
• IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity

  2017cited by this paper
• Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

  2017cited by this paper
• Insulin-like growth factor binding protein-2 interactions with Alzheimer’s disease biomarkers

  2017cited by this paper
• Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects

  2016cited by this paper
• Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta‐analysis

  2015cited by this paper
• Serum IGF-BP2 strongly moderates age's effect on cognition: a MIMIC analysis.

  2015cited by this paper
• Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.

  2015cited by this paper
• Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms.

  2015cited by this paper
• IGFBP-2 - taking the lead in growth, metabolism and cancer

  2015cited by this paper
• Prenatal stress leads to changes in IGF-1 binding proteins network in the hippocampus and frontal cortex of adult male rat.

  2014cited by this paper
• Control of IGFBP-2 Expression by Steroids and Peptide Hormones in Vertebrates

  2014cited by this paper
• Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides.

  2014influential reference
• Prenatal stress leads to changes in IGF-1 binding proteins network in the hippocampus and frontal cortex of adult male rat

  2014cited by this paper
• Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.

  2013influential reference
• Effects of antipsychotic medications on appetite, weight, and insulin resistance.

  2013cited by this paper
• High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men.

  2012cited by this paper
• Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice

  2012cited by this paper
• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)

  2011cited by this paper
• Antidiabetic effects of IGFBP2, a leptin-regulated gene.

  2010cited by this paper
• A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T)

  2010cited by this paper
• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

  2009cited by this paper
• IGF-Binding Protein-2 Protects Against the Development of Obesity and Insulin Resistance

  2007cited by this paper
• Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.

  2006cited by this paper
• Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.

  2004influential reference
• Effect of type 2 diabetes on various electrophoretic characteristics of low-density lipoprotein particles in women

  2004cited by this paper
• New guidelines for low-density lipoprotein levels from the National Cholesterol Education Program (NCEP): a 2004 update.

  2004cited by this paper
• Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

  2000cited by this paper
• Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry

  1993cited by this paper
• Anthropometric Standardization Reference Manual

  1988cited by this paper
• Stature, recumbent length, and weight

  1988cited by this paper
• Immunoturbidimetric determination of apolipoproteins A-1 and B in serum.

  1987cited by this paper
• Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.

  1987cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• [Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method].

  1971cited by this paper
• Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays.

  1971cited by this paper

• Proteomic Profiling of IGFBP2: Modulation and Biomarker Potential in Atherosclerotic Cardiovascular Disease Prevention

  2025cites this paper
• Association of Atypical Antipsychotics With Lipid Abnormalities in Adult Patients With Schizophrenia: A Scoping Review

  2025influential citation
• Multidimensional Epigenetic Clocks Demonstrate Accelerated Aging Across Physiological Systems in Schizophrenia: A Meta-Analysis

  2024cites this paper
• Effectiveness of Risperidone Use with Side Effects of Metabolic Syndrome in Patients with Mental Disorders: Systematic Literature Review

  2024cites this paper
• Insulin-like Growth Factor 2 (IGF-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) Are Upregulated after Atypical Antipsychotics in Spanish Schizophrenia Patients

  2022cites this paper